Paladin Labs Launches Xydalba In Canada - Quick Facts

(RTTNews) - Paladin Labs Inc., a unit of Endo International plc (ENDP), said Xydalba (dalbavancin for injection), a 30-minute intravenous therapy for acute bacterial skin and skin structure infections that can be administered as a single- or two-dose regimen, is now available to patients nationwide in Canada.

In April 2021, ADVANZ PHARMA Corp. and Endo announced that Endo subsidiary Endo Ventures Limited had entered into a definitive agreement with Correvio International Sàrl, a subsidiary of ADVANZ PHARMA, to commercialize Xydalba in Canada on an exclusive basis.